Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies
“The advancement of our unique oral multi-kinase inhibitor into the clinic indicates the promising biological activities of S*BIO’s pre-clinical compounds,” said Dr. Jan-Anders Karlsson, CEO of S*BIO. “SB1317 has a unique kinase inhibitory spectrum with excellent pharmaceutical properties for the potential treatment of acute leukemia, multiple myeloma and several solid tumors including breast cancer, small-cell lung cancer and colon cancer. S*BIO intends to utilize the proceeds to further advance its clinical program.”
In January 2009, S*BIO granted a worldwide exclusive license to Tragara to develop and commercialize SB1317. Under the terms of the agreement S*BIO was eligible to receive up to US$112.5 million in payments. This included an upfront fee, development and sales milestone payments and up to doubledigit royalties. Additionally, S*BIO would perform certain preclinical activities for Tragara under a defined workplan in return for research fees. Tragara was responsible for all IND enabling, development and commercialization activities under the agreement.
Tragara will conduct the Phase 1 study at multiple clinical centers in the U.S. SB1317 will be administered orally to patients with advanced leukemia over a range of doses on two separate schedules. Patients with relapsed multiple myeloma will be enrolled onto a separate arm of the trial. The trial’s objective is to determine the dose-limiting toxicity, maximum-tolerated dose, and recommended dose of SB1317 for a Phase 2 study. Secondary objectives include the assessment of the pharmacokinetic profile of SB1317, evaluation of exploratory biomarkers and presence of polymorphisms of genes involved in the metabolism of SB1317. Evidence of anti-tumor activity will also be assessed by objective response, progression-free survival and overall survival. In the near future, Tragara will initiate a Phase 1 study of SB1317 in patients with solid tumors.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.